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Comparison of remifentanil 
versus fentanyl general 




Study objectives. To compare the effect of remifentanil versus fentanyl isoflurane general anesthesia on Aldrete score, 
emergence, extubation and discharge times from the operating room (OR) and postanesthesia care unit (PACU) following 
short outpatient urologic procedures (panendoscopy and cystoscopy, bladder hydrodilatation, stent placement).
Patients and methods. 40 patients 18 years of age or older scheduled for short elective outpatient urological procedures 
with an expected duration of less than 30 minutes.
Following Institutional Review Board (IRB) approval and written informed consent, 40 American Society of Anesthesiologi-
sts (ASA) physical class 1-3 adult outpatients were enrolled and equally (n=20) randomized into remifentanil and fentanyl 
groups. Preoperatively, all subjects received intravenous (IV) midazolam 1-2 mg and were induced with propofol 2 mg/
kg IV. Muscle relaxation was achieved with succinylcholine or rocuronium, followed by intubation. The remifentanil group 
received remifentanil 1 g/kg IV at induction with a maintenance dose of remifentanil 0.1 to 2 g/kg/min IV in the presence 
of 60% nitrous oxide (N2O)/40% oxygen (O2) and end-tidal isoflurane of 0.3 to 0.4% (for amnesia). The fentanyl group 
received fentanyl 2 g/kg IV at induction, maintenance dose of fentanyl 2 to 3 g/kg IV intermittent bolus, and 60% N2O/40%
O2 with 2% end-tidal isoflurane. Muscle relaxation was reversed at the end of anesthesia as needed. Times for OR entry, 
emergence, extubation, total OR time (entry to exit) and PACU discharge time, as well as Aldrete scores at time of OR exit 
and PACU discharge were determined. Data was evaluated by ANOVA, t-test and Mann-Whitney tests. A p<0.05 value 
was considered statistically significant.
Results. There was no significant difference between groups in age, gender, weight, ASA class, PACU analgesic or antie-
metic use, or times of emergence, extubation, OR exit and PACU discharge. There was a significant difference (p<0.05) in 
OR exit Aldrete score but not PACU discharge Aldrete score. No adverse events were noted.
Conclusions. While there was no difference between the remifentanil and fentanyl groups regarding recovery time from 
OR and PACU, remifentanil patients had significantly better OR exit Aldrete scores with less sedation upon arrival at phase 
I PACU recovery than the fentanyl group. This anesthesia technique may prove helpful for fast-track eligibility of these 
patients.  
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Introduction
Recent advancements in urology pro-
cedures and instruments have resulted 
in an increased number of minimally 
invasive outpatient urological procedu-
res. (1) These procedures, while short in 
duration (<30-40 minutes), can intrao-
peratively be stimulating and uncomfor-
table for the patient, but postoperatively 
may be associated with minimal pain. 
Patient emergence, extubation and dis-
charge from the operating room and 
postanesthesia care unit are important 
time points for recovery of outpatients 
receiving general anesthesia. The goal 
of outpatient anesthesia and analgesia 
is to provide a surgical stage of ane-
sthesia that can be induced quickly and 
resolved rapidly after discontinuing its 
administration, allowing for the rapid 
recovery of the patient to baseline pre-
24 www.signavitae.com
anesthetic mental and physical functi-
oning. Anesthesia during urologic pro-
cedures provides for patient comfort, 
and by immobilizing the patient increa-
ses patient safety as perforation of the 
bladder or ureter resulting from patient 
movement can occur when these areas 
are instrumented. (1,2) Outpatient ane-
sthesia consists of a variety of anesthe-
tic combinations, which include intrave-
nous sedatives, hypnotics, and opioids 
as well as inhalation agents.
Remifentanil (Ultiva; Abbott Labs, 
Inc., Abbott Park, IL) is an ultra-short 
acting opioid with a serum half-life of 
nine minutes. Remifentanil is metabo-
lized by nonspecific plasma and tissue 
esterases, resulting in the rapid offset of 
effect when its administration is discon-
tinued. (3,4)  Prior research has deter-
mined that remifentanil: 1) is effective 
in blunting the increased hemodynamic 
responses of heart rate (HR) and blood 
pressure (BP) following induction of 
anesthesia and surgical stimuli; (5) 2) 
decreases the minimum alveolar con-
centration (MAC) requirements of inha-
lation agents; (6) 3) produces dose-de-
pendent analgesia when administered 
as part of a balanced anesthetic tech-
nique. (7)  Due to the short duration of 
action of remifentanil, an increase in 
postoperative pain may occur once its 
administration is discontinued. Proce-
dures that are associated with modera-
te to major postoperative pain require 
the addition of longer acting pain medi-
cations (i.e. fentanyl, morphine) during 
the end of anesthesia and prior to the 
end of remifentanil infusion to ensure 
patient analgesia and comfort. 
Patient emergence, extubation and dis-
charge from the operating room and 
post anesthesia care unit are important 
time points for recovery of outpatients 
receiving general anesthesia. Due to its 
ultrashort duration of action and rapid 
recovery time, remifentanil appears to 
be an ideal drug to incorporate into 
a balanced N2O, O2, opioid, muscle 
relaxant anesthesia plan for brief outpa-
tient procedures associated with mini-
mal or no postoperative pain.
Cost containment is a continual and 
important concern in health care. While 
remifentanil has a higher g/dollar 
cost compared to older, longer acting 
opioids (morphine, fentanyl) or inha-
lation anesthetic agents (halothane, 
isoforane), the time in the OR or PACU 
theoretically could be decreased by 
remifentanil use. The purpose of this 
study was to compare the effect of 
remifentanil versus fentanyl isoflurane 
general anesthesia on Aldrete scores, 
emergence, extubation and discharge 
times from OR and PACU following 
short outpatient urologic procedures 
(panendoscopy and cystoscopy, blad-
der hydrodilatation, stent placement) 
with an expected duration of less than 
30 minutes.
Methods
Following IRB approval and written infor-
med consent, 40 ASA physical class 1-3 
adult male and female patients schedu-
led for outpatient urological procedures 
under general anesthesia were enrolled 
in this randomized, prospective, open-
label, single-blind study. Inclusion and 
exclusion criteria are listed in table 1. 
Subjects were randomly assigned to 
one of two study groups (remifentanil 
or fentanyl) by picking numbers from a 
hat. Baseline vital signs were obtained 
and included BP via non-invasive cuff, 
HR via electrocardiogram, and O2 satu-
ration (SpO2) via pulse oximeter. Study 
subjects were equally divided (n=20 
each) into remifentanil and fentanyl 
groups. All subjects received midazo-
lam 1-2 mg IV as premedication, and 
general anesthesia was induced with 
propofol 2 mg/kg IV. Muscle relaxation 
was accomplished with succinylcholine 
or rocuronium, followed by intubation. 
The remifentanil group received remi-
fentanil 1 g/kg IV at induction and a 
maintenance dose of remifentanil 0.1 
to 2.0 g/kg/min IV in the presence 
of 60% N2O/40% O2 and 0.2 to 0.4% 
end-tidal isoflurane (for amnesia). The 
fentanyl group received fentanyl 2 g/
kg IV at induction, a maintenance dose 
of fentanyl 2 to 3 g/kg IV in the pre-
sence of 60% N2O/40% O2 and 2% 
end-tidal isoflurane. When surgery was 
completed, all anesthetic agents were 
discontinued, and study subjects were 
allowed to recover from anesthesia. 
Muscle relaxation was reversed at the 
end of anesthesia as needed. The 
endotracheal tube was removed when 
the subjects’ respiratory rate was >12 
breaths per minute and they could lift 
their heads for three seconds, squeeze 
their hand and open their eyes on com-
mand. Study subjects were then moved 
to a cart and transported to the PACU 
with 100% O2 via a face mask. Times 
for OR entry, emergence, extubation, 
total OR (entry to exit) and PACU dis-
charge, as well as Aldrete scores at 
time of OR exit and PACU discharge 
were determined. Protocol schema is 
diagrammed in figure 1.
The time points studied were elapsed 
time from: 1) end of operation to extu-
bation; 2) end of operation to exit from 
the OR suite; 3) OR exit to arrival at 
phase 1 PACU recovery: 4) phase 1 
exit to discharge from phase 2 PACU 
recovery. Variables also analyzed were 
the type and amount of opioid and anti-
emetic medications used in the PACU. 
Postoperative care for analgesics and 
antiemetics was conducted according 
to PACU protocol.
Demographic data were obtained on 
each patient, including age, weight, 
height, gender and ASA classificati-
on. Medications, dosages, and time of 
initiation and discontinuation of study 
medications were determined, inclu-
Table 1.  Inclusion/Exclusion  
criteria.
Inclusion Criteria
1. ASA physical class I, II or III
2. Females or males age 18 years or older
3. Subjects who are scheduled for outpa-
tient urological procedures requiring 
general anesthesia
Exclusion Criteria
1. Subjects who were scheduled for admi-
ssion to the hospital postoperatively
2. ASA physical class IV or V
3. Pregnant females
4. Subjects who were dependent on opi-
oids
5. Subjects with allergies to opioids, eggs, 
soy protein or propofol
ASA, American Society of   
Anesthesiologists. 
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ding the type and amount of IV fluids 
administered. Information regarding 
the type of procedure performed, ope-
rative start and stop times, OR arrival 
and departure times, time of placement 
and removal of the endotracheal tube, 
and details regarding any perioperative 
adverse events were noted. An Aldrete 
score was assessed for each patient at 
the time of departure from the OR suite 
and at the time PACU discharge crite-
ria were met. A special notation was 
made if the subject met discharge cri-
teria but was unable to leave the PACU 
for reasons beyond the control of the 
investigator. Postoperative information 
included PACU arrival and departure 
times and the type and amount of IV 
fluids or other medications (opioids, 
antiemetics) administered. Any adverse 
events were noted.  All subjects were 
interviewed within 24 hours of hospital 
discharge regarding their perception 
of their anesthetic experience and the 
occurrence of any adverse events.
This study compared time elapsed 
from the end of the surgical procedu-
re to extubation and exit from the OR 
between subjects receiving remifentanil 
versus fentanyl general anesthesia. The 
degree of discharge readiness, use of 
opioids or antiemetics in the PACU, 
and the amount of time the subjects 
were in the PACU were compared 
between groups. Data were evaluated 
by ANOVA, t-test and Mann-Whitney 
tests. A p<0.05 value was set for stati-
stical significance.
Results
There was no difference between gro-
ups in age, gender, weight, height, 
ASA physical class, PACU analgesic 
(fentanyl) or antiemetic use (table 2). 
There was no difference between gro-
ups in total OR medications (table 3). 
While there was no difference in times 
of emergence, extubation, OR exit and 
PACU discharge. There was a signifi-
cant difference (p<0.05) between gro-
ups in OR exit Aldrete score but not 
PACU discharge Aldrete score (table 
4). No adverse events were noted.
No statistically significant difference 
was found in the occurrence of posto-
perative nausea and vomiting (PONV) 
or postoperative pain between the two 
study groups. However, the PACU 
times for subjects who experienced 
both PONV and pain in both study 
groups was substantially longer than 
subjects who experienced none or only 
one of these postanesthesia adverse 
events. No statistically significant dif-
ference was found between groups for 
the time from the end of the procedure 
to extubation and departure from the 
OR suite. Only a marginal statistically 
significant difference (p=0.058) was 
found between groups regarding the 
PACU length of stay (mean + SD) with 
the time being 50.1 ± 10.87 and 63.0 ± 
12.67 minutes for the remifentanil and 
fentanyl groups, respectively. However, 
there appeared to be clinical signifi-
cance since the remifentanil group had 
attained a higher Aldrete score (10.0) 
earlier (at the time of OR exit) and was 
able to leave the PACU within 60 minu-
tes on average of arrival.
Discussion
The progression of many urology pro-
cedures from inpatient to outpatient 
status has occurred over the past seve-
ral years. Continued advancement in 
surgical equipment and techniques, 
as well as an increased focus on cost 
containment has facilitated this change 
in urology. (2) A retrospective study 
by Kaye (1) determined that urology 
outpatient procedures increased from 
26% in 1987 to 42% in 1992. The sur-
gical sites with the largest increases in 
outpatient urology procedures included 
the kidney, ureter, and urethra.
With an increasing number of outpa-
tient surgical procedures, the field of 
anesthesia is challenged with deve-
loping an anesthetic plan that provi-
des patient comfort and optimal con-
ditions for the surgeon, allowing for 
rapid patient emergence, recovery and 
discharge with minimal or no postane-
sthesia adverse events. This has led 
to the research and development of 
short acting anesthetic medications 
Meet inclusion criteria 
Preoperative Midazolam 1-2 mg IV 
Randomization 
         Remifentanil Group  Fentanyl Group 
             (n=20)        (n=20) 
Anesthesia Induction Propofol 1-2 mg/kg   Propofol 1-2 mg/kg 
    Remifentanil 0.5-1.0 g/kg  Fentanyl 1-2 g/kg
    Muscle relaxant for    Muscle relaxant for 
    Intubation    intubation 
Anesthesia Maintenance    N2O/O2 60%/40%   N2O/O2 60%/40% 
Isoflurane 0.4% end-tidal  Isoflurane 1-2% end-tidal 
    Remifentanil 0.1-2 g/kg  Fentanyl 2-3 g/kg
    Muscle relaxant prn   Muscle relaxant prn 
Muscle relaxant reversal  Muscle relaxant reversal 
    (as needed)    (as needed) 
       
Emergence    Emergence 
Awakening    Awakening 
Figure 1. Protocol schema.
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that enable patients to regain cognitive 
and psychomotor functions in a more 
timely fashion, with minimal side effects 
allowing for earlier discharge home.
Remifentanil has been investigated and 
is used as a short acting opioid in balan-
ced anesthesia for outpatient surgery. 
Burkle and colleagues, (5) determined 
that remifentanil was an ideal opioid 
for short, painful procedures in the OR, 
emergency room and intensive care 
units. They emphasized that remifenta-
nil does not provide for postoperative 
analgesia when its administration is dis-
continued. Thus, the initiation of longer 
acting analgesics or local anesthetic 
techniques prior to emerging from ane-
sthesia is required to prevent the imme-
diate onset of pain and discomfort after 
completion of procedures associated 
with continued postoperative pain. 
Thompson et al. (8) determined that 
remifentanil effectively attenuated sym-
pathetic stimulation induced by orotra-
cheal intubation. Lang et al. (6) found 
that remifentanil caused a correspon-
ding reduction in the minimum alveolar 
concentration of isoflurane. Both the 
remifentanil and fentanyl groups in our 
study utilized isoflurane as an inhalation 
agent. However, the use of isoflurane 
was different between groups. In the 
remifentanil group, a low end-tidal dose 
of isoflurane 0.3 to 0.4% (¼ to 1/3 MAC) 
was used as the secondary anesthetic 
for amnesia in combination with remi-
fentanil as the primary anesthetic for 
analgesia. In the isoflurane group, a 
2% end-tidal isoflurane concentration 
(1.67% MAC) was used as the primary 
anesthetic in combination with fenta-
nyl as the secondary anesthetic. The 
anesthetic end-point for both groups 
was the blunting of intraoperative sur-
gical stress responses as exhibited by 
tachycardia and hypertension.
There continues to be an increase in the 
number of short, stimulating outpatient 
urology procedures such as panendos-
copy and cystoscopy, bladder hydro-
dilatation for interstitial cystitis, ureteral 
stent placement and extracorporeal 
shock wave lithotripsy for kidney or ure-
teral stones. (1,2) These procedures 
usually require more sedation and anal-
gesia than can be given by monitored 
anesthesia care alone, as often these 
procedures are associated with mode-
rate intraoperative and postoperative 
pain and discomfort. With an increased 
emphasis on cost containment and 
shorter PACU stays, remifentanil appe-
ared to be an ideal opioid choice for 
balanced anesthesia during these short 
outpatient urological cases. However, 
the present study determined no clini-
cally significant (mean time difference 
of 1.5 minutes) or statistically signifi-
cant difference between the time from 
the end of the surgical procedure to the 
time of extubation comparing remifen-
tanil to the fentanyl.   
No clinical or statistical significance was 
found comparing the difference in time 
spent in the OR suite after termination 
of the surgical procedure to departure 
from the OR suite. The fentanyl group 
(mean +SD, 9.55+2.54 minutes) exited 
0.3 minutes earlier than the remifentanil 
group (9.85+4.40 minutes, table 4). 
Remifentanil may prove to be useful 
to shorten recovery time following long 
surgical procedures. However, com-
pared to fentanyl, remifentanil did not 
shorten OR exit time following short 
30-40 minute urological procedures.  
Comparison of the difference in the 
amount of time each group spent in the 
PACU revealed only marginal statistical 
significance (p=0.058). This marginal 
difference in PACU time may be attribu-
ted to the more rapid attainment of disc-
harge criteria to an Aldrete score of 10 by 
the remifentanil group. However, there 
was no significant difference between 
groups in PACU Aldrete discharge 
scores at the time of PACU discharge. 
While there was no difference between 
groups regarding recovery times from 
OR and PACU, the remifentanil groups 
had significantly better OR exit Aldrete 
scores (10 out of 10) with less sedation 
than the fentanyl group (9 out of 10). 
The subjects in the remifentanil group 
had mean (+SD) Aldrete scores of 9.50 
+ 0.51 upon discharge from the OR 
suite as opposed to a mean score of 
8.65 + 1.34 for subjects in the fentanyl 
group. This finding may be attributed to 
remifentanil’s short elimination half-life 
and less sedation in conjunction with a 
lower end-tidal isoflurane concentrati-
on compared to the fentanyl-isoforane 
group. This could have clinical and eco-
nomic significance, since the remifenta-
nil group achieves an Aldrete score of 
10 earlier than the fentanyl group, and 
on average was able to leave the PACU 
within 60 minutes of arrival.  
There was no statistical difference in the 
total PACU use (mean + SD) of opioids 
(fentanyl) (50 + 9.8 g) versus remifen-
tanil (60.71 + 10.2 g) between the two 
groups. The fentanyl group included 
study subjects who were successfully 
treated with IV ketorolac (30 mg) and 
acetaminophen (650 mg) as opposed 
to only opioid medications. It should 
be noted that the differences of anal-
Table 2.  Patient demographics.
REMIFENTANIL FENTANYL P
n 20 20
+Age, years 48 (28-60) 40 (25-55) 0.0791
*Weight, kg 77.20 ± 14.49 81.00 ± 25.88 0.0956
Height, in 66.25 ± 3.9 66.68 ± 4.41 0.494
Gender
Males















*Above weight and height values are mean + SD
+Above age values are expressed as median (range)
 ASA, American Society of Anesthesiologists.
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gesic choice between the remifentanil 
and fentanyl groups were related more 
to the first-line opioid chosen by the 
anesthesia provider as opposed to the 
severity of the pain experienced by the 
study subjects.  
The number of patients experiencing 
postoperative pain in the PACU was 
identical (n=6) in the two study gro-
ups. The mean visual analog pain score 
reported for those experiencing posto-
perative pain in the fentanyl group was 
4.8 compared to a score of 5.4 in the 
remifentanil group (visual analog scale 
from 0, no pain, to 10, maximum pain). 
The remifentanil group had two outlying 
pain scores of 10. One subject was a 
25-year old female who required 300 
g IV fentanyl, 30 mg IV ketorolac and 
two oxycodone / acetaminophen oral 
pain medications to relieve her posto-
perative pain. Fifty-five minutes were 
required to attain adequate pain con-
trol for this subject, which resulted in 
a total PACU time of 86 minutes. The 
other subject who reported a pain score 
of 10 was a 37-year-old female who 
preoperatively reported having chronic 
pain (equal to a pain score of 6 to 7 
out of a possible 10) on a daily basis. 
This subject was successfully treated 
with two oxycodone / acetaminophen 
tablets and one B & O (Belladonna and 
Opium) suppository. Total PACU time 
for this subject was 65 minutes, which 
was approximately 15 minutes longer 
than the mean PACU time for this study 
group. If the aforementioned outlying 
patient who required 300 g of fentanyl 
is excluded, the mean (+ SD) dose of 
PACU fentanyl becomes 41.67 + 11.6 
g for the fentanyl group compared to 
60.71 + 10.2 g/kg for the remifentanil 
group. This does not appear to have 
any clinical or cost significance, as the 
doses of IV opioids are administered 
from ampoules that contain either 100 
or 500 g of fentanyl. In our hospital 
pharmacy, excess IV opioid medicati-
ons cannot be used for other patients. 
Any unused portion is subsequently 
wasted, with the entire ampoule being 
charged to that patient.  
The incidence of PONV was similar, 
occurring in 3 and 4 patients for the 
fentanyl and remifentanil groups, res-
pectively. The mean nausea scores 
(1=no nausea, 10=worst nausea) 
were 1 and 2, for the fentanyl and the 
remifentanil groups, respectively. The 
number of antiemetic doses required 
to treat PONV in the PACU was 4 and 2 
doses, respectively, for the fentanyl and 
remifentanil groups (table 3).  
The PACU times associated with pati-
ents who experienced postoperative 
complications such as pain, nausea 
and vomiting were substantially lon-
ger than patients who had no posto-
perative complications. The mean (+ 
SD) PACU time for all subjects in the 
study who had an uneventful recovery 
was 51.36 (+15.56) minutes. Intere-
stingly, three subjects experienced only 
PONV and had a mean PACU time of 
42.33 (+13.42) minutes. Eight subjects 
experienced only pain and had a mean 
PACU time of 59.145 (+ 20.52) minu-
tes. Four subjects experienced both 
PONV and pain and had a mean PACU 
time of 94.5 (+22.4) minutes. These 
findings continue to support previous 
literature findings regarding increased 
length of stay and costs associated 
with these postoperative complications. 
(9,10) These subjects had increased 
postoperative costs due to increased 
recovery time and additional medicati-
on and supply charges.  
Propofol was used as the IV induction 
agent in this study. Numerous studies 
(7,11,12) have compared propofol and 
thiopental for induction of anesthesia 
in the outpatient population and have 
determined that recovery from propo-
fol occurs significantly more rapidly 
than from thiopental. Korttila et al. (12) 
found impaired objective performance 
on psychomotor tests at one hour after 
propofol with no detectable impairment 
after three hours. However, subjects 
who received thiopental had signifi-
cantly impaired psychomotor perfor-
mance at five hours after administrati-
on. An additional advantage of propofol 
is its antiemetic effects. (7,11)
Studies conducted by Sengupta and 
Plantevin (13) and Sukhhani et al. (14) 
determined that the addition of N2O to 
propofol for maintenance of anesthesia 
in outpatient laparoscopic procedures 
reduced the amount of propofol requi-
red to maintain anesthesia. This resul-
ted in a significantly shorter time to eye 
opening and orientation than in patients 
who did not receive N2O.  
Remifentanil is an ultra-short acting 
opioid that produces effects similar to 
other opioids, including attenuation of 
hemodynamic responses to noxious sti-
muli and dose-dependent reductions in 
the MAC of volatile anesthetics. (4,8) The 
decreased dose of 0.3 to 0.4% (¼ to 1/3 










177.00 ± 31.61 0.0769
Total Midazolam 
















60.71 + 10.2 50.0 + 9.8 0.0876
PACU, postanesthesia care unit.
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MAC) of isoflorane was used in the remi-
fentanil groups to help ensure amnesia. 
Remifentanil, like other opioids, has been 
shown to reduce the MAC of volatile 
anesthetic agents in a dose-dependent 
fashion. Burke et al. (5) determined that 
the MAC of isoflurane was decreased 
by 12 to 91% depending on the plasma 
concentration of remifentanil. Lange and 
coworkers (6) have suggested that, due 
to its short duration of action, remifenta-
nil should be maintained at higher levels 
initially and titrated to clinical effect while 
administering an anesthetic gas, such 
as isoflurane, at levels slightly above 
MAC awake. They suggested that this 
will maintain an adequate anesthetic 
state, allowing for rapid awakening wit-
hout a prolonged recovery time due to 
respiratory depression.  
The chemical structure of remifentanil is 
metabolized by nonspecific blood and 
tissue esterases with no dependence 
on redistribution or liver metabolism, 
resulting in its rapid and immediate eli-
mination upon discontinuation. Remi-
fentanil has an elimination half-life of 
approximately 9 minutes. (4,5) Prolon-
ged administration or continuous infu-
sion of remifentanil does not result in 
tissue accumulation or alter its half-life 
and speed of elimination. (3,4) Remi-
fentanil does not provide postoperative 
analgesia when its administration is 
discontinued. Thus, prior to emergen-
ce from anesthesia, it is necessary to 
initiate longer acting analgesics, local 
anesthetics or other means of pain con-
trol to prevent the immediate onset of 
pain after the completion of surgical 
procedures associated with moderate 
to severe postoperative pain.  
With the continued increase in the num-
ber of short, stimulating urological pro-
cedures that are associated with mini-
mal postoperative discomfort, and the 
increased focus on cost containment 
with shorter PACU stays, remifenta-
nil appears to be an alternative opio-
id choice for balanced anesthesia in 
these cases, allowing for rapid reco-
very and the “fast tracking” of these 
outpatients. However, except for less 
sedation at the time of OR exit, remifen-
tanil offered no additional advantages 
over the standard fentanyl isoforane 
general anesthesia technique for these 
short outpatient urology procedures. 
An explanation for this could be the 
relatively short duration of the urologi-
cal procedures chosen, 34.45 + 22.10 
(mean +SD) minutes, for the fentanyl 
group compared to 41.85 + 20.21 for 
the remifentanil group, with no statisti-
cal difference in duration between the 
two groups. For short, low-stimulating 
surgeries, the difference in % end tidal 
isoflurane concentration (maximum % 
minus minimum %) used for inhalation 
anesthesia between the remifentanil 
and fentanyl groups 1.33% (1.63 minus 
0.31.7%) and (2.0 minus 0.3%), respec-
tively, was small. In addition, in relatively 
lean patients during short surgical pro-
cedures, the amount of isoflurane gas 
absorbed by the study patients was not 
large enough to prolong their wake-up. 
In conclusion, with an increased num-
ber of outpatient urological surgery pro-
cedures, there is a challenge to provide 
analgesia and amnesia while allowing 
for rapid recovery and minimal posta-
nesthesia complications. For short out-
patient urologic procedures, there was 
no difference between remifentanil and 
fentanyl isoflurane general anesthesia 
regarding anesthesia duration, extu-
bation, OR exit and PACU discharge 
times. However, remifentanil patients 
had significantly better OR exit Aldrete 
scores with less sedation than the fen-
tanyl group. This may prove helpful for 
the fast-track eligibility of these patients 
and deserves further investigation.















*p<0.05 compared to fentanyl group
Data values = mean + SD
PACU, postanesthesia care unit; OR, operating room.
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